Tyck till om SwePub Sök
här!
Search: WFRF:(Lovestone Simon)
> Research review >
Biomarkers for Alzh...
Biomarkers for Alzheimer's disease therapeutic trials.
-
Hampel, Harald (author)
-
Wilcock, Gordon (author)
-
Andrieu, Sandrine (author)
-
show more...
-
Aisen, Paul (author)
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Broich, K (author)
-
Carrillo, Maria (author)
-
Fox, Nick C (author)
-
Frisoni, Giovanni B (author)
-
Isaac, Maria (author)
-
Lovestone, Simon (author)
-
- Nordberg, Agneta (author)
- Karolinska Institutet
-
Prvulovic, David (author)
-
Sampaio, Christina (author)
-
Scheltens, Philip (author)
-
Weiner, Michael (author)
-
- Winblad, Bengt (author)
- Karolinska Institutet
-
Coley, Nicola (author)
-
Vellas, Bruno (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2011
- 2011
- English.
-
In: Progress in neurobiology. - : Elsevier BV. - 1873-5118 .- 0301-0082. ; 95:4
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- The development of disease-modifying treatments for Alzheimer's disease requires innovative trials with large numbers of subjects and long observation periods. The use of blood, cerebrospinal fluid or neuroimaging biomarkers is critical for the demonstration of disease-modifying therapy effects on the brain. Suitable biomarkers are those which reflect the progression of AD related molecular mechanisms and neuropathology, including amyloidogenic processing and aggregation, hyperphosphorylation, accumulation of tau and neurofibrillary tangles, progressive functional, metabolic and structural decline, leading to neurodegeneration, loss of brain tissue and cognitive symptoms. Biomarkers should be used throughout clinical trial phases I-III of AD drug development. They can be used to enhance inclusion and exclusion criteria, or as baseline predictors to increase the statistical power of trials. Validated and qualified biomarkers may be used as outcome measures to detect treatment effects in pivotal clinical trials. Finally, biomarkers can be used to identify adverse effects. Questions regarding which biomarkers should be used in clinical trials, and how, are currently far from resolved. The Oxford Task Force continues and expands the work of our previous international expert task forces on disease-modifying trials and on endpoints for Alzheimer's disease clinical trials. The aim of this initiative was to bring together a selected number of key international opinion leaders and experts from academia, regulatory agencies and industry to condense the current knowledge and state of the art regarding the best use of biological markers in Alzheimer's disease therapy trials and to propose practical recommendations for the planning of future AD trials.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Psykiatri (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Psychiatry (hsv//eng)
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hampel, Harald
-
Wilcock, Gordon
-
Andrieu, Sandrin ...
-
Aisen, Paul
-
Blennow, Kaj, 19 ...
-
Broich, K
-
show more...
-
Carrillo, Maria
-
Fox, Nick C
-
Frisoni, Giovann ...
-
Isaac, Maria
-
Lovestone, Simon
-
Nordberg, Agneta
-
Prvulovic, David
-
Sampaio, Christi ...
-
Scheltens, Phili ...
-
Weiner, Michael
-
Winblad, Bengt
-
Coley, Nicola
-
Vellas, Bruno
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Psychiatry
- Articles in the publication
-
Progress in neur ...
- By the university
-
University of Gothenburg
-
Karolinska Institutet